Clinical implications of chromosomal aberrations (13q14 and 17p13 deletion, translocation t(4;14) and 1q21 amplification) in patients with relapsed multiple myeloma treated by thalidomide or bortezomib (Velcade)

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Science. Official publication website can be found on muni.cz.
Authors

ZAORALOVÁ Romana KUGLÍK Petr FILKOVÁ Hana GREŠLIKOVÁ Henrieta NĚMEC Pavel OLTOVÁ Alexandra POUR Luděk ADAM Zdeněk KŘIVANOVÁ Andrea KREJČÍ Marta HÁJEK Roman

Year of publication 2007
Type Article in Proceedings
Conference From cell sorting to plasma cell identification and chromosomal aberrations in multiple myeloma – Application manual
MU Faculty or unit

Faculty of Science

Citation
Field Genetics and molecular biology
Keywords Multiple myeloma; CKS1B amplification; RB deletion; p53 deletion; t(4;14); cIg FISH
Description The aim of the work was: 1) To study the incidence of the chromosomal aberrations known as adverse prognostic factors in MM - deletion of 13q14 (RB1), deletion of 17p13 (p53), amplification of 1q21 (CKS1B) and translocation t(4;14) in a group of 40 patients with relapsed MM. 2) To compare the prognostic and predictive significance of these unfavorable chromosomal aberrations in patients with relapsed MM treated with thalidomide or bortezomib (Velcade) based regimens.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.